Lupus Erythematosus, Systemic: all 1,222 studies

Page 7 of 13. Open to participants first (399), then studies with results posted, then the rest; newest registration first within each.

• Efficacy of Vitamin C Supplementation on Serum TNF-α Levels and Disease Activity in SLE PatientsCompletedNCT07071233Not applicable
• Efficacy of Vitamin C Supplementation on Serum IL-6 Levels and Disease Activity in Systemic Lupus Erythematosus PatientsCompletedNCT07071220Not applicable
• A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus Involving Multiple Units, Based on Previous Data.Active, not recruitingNCT07053137
• Efficacy of Synbiotic Supplementation on IL-10, TGF-B and Disease Activity in Systemic Lupus Erythematosus PatientsCompletedNCT07048470Not applicable
• Water-based Liuzijue Exercise on Childhood-onset Systemic Lupus ErythematosusCompletedNCT07024082Not applicable
• A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)Active, not recruitingNCT07015983Phase 2
• The Frequency of Thiopurine Methyltransferase Polymorphism in Systemic Lupus Erythematosus SLECompletedNCT07012239
• Occupational and Environmental Causes of Autoimmune DiseasesCompletedNCT07000903Not applicable
• A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)WithdrawnNCT06984341Phase 1
• A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus ErythematosusCompletedNCT06955598Phase 1
• Hematological Manifestations in Systemic Lupus Erythematosus PatientsCompletedNCT06936007
• C-CAR168 CAR T Cell Therapy for Refractory Autoimmune DiseaseWithdrawnNCT06935474Phase 1/2
• A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune DiseasesWithdrawnNCT06913608Phase 1
• Adjunctive Yu-Tone Music Therapy for Systemic Lupus Erythematosus: a Prospective Cohort StudyActive, not recruitingNCT06898489
• A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune DiseasesWithdrawnNCT06866080Early Phase 1
• A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)Active, not recruitingNCT06799520Phase 1
• Systemic Immune Inflammatory Index in Systemic Lupus ErythematosusCompletedNCT06796569
• Clinical and Demographic Features of Patients With Moderate to Severe Active Systemic Lupus Erythematosus in RussiaCompletedNCT06759519
• CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)WithdrawnNCT06752876Phase 1
• Whole Health Empowerment for Endotypes of Lupus: Improving Quality of Life in SLECompletedNCT06720584Not applicable
• This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients With SLECompletedNCT06698900
• Immune Cell Subsets in SLE Patients Treated with TelitaciceptActive, not recruitingNCT06677801Phase 4
• Anifrolumab Real-world Treatment Outcomes in Systemic Lupus ErythematosusActive, not recruitingNCT06673043
• Efficacy of Seluang Fish Oil (Rasbora Argyrotaenia) and Synbiotics Supplementation on CD4+CD25+ Foxp3+ T-regulator Cells, IL17/IL-10 Ratio, and Disease Activity in Systemic Lupus Erythematosus PatientsActive, not recruitingNCT06659068Not applicable
• Headache in Juvenile Onset Systemic Lupus ErythematosusCompletedNCT06658457
• A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus ErythematosusCompletedNCT06653556Early Phase 1
• Fatigue in Systemic Lupus ErythematosusCompletedNCT06652256
• AZAHAR Study To Describe Anifrolumab in a Real-World SettingCompletedNCT06626945
• A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)Active, not recruitingNCT06581198Phase 2
• Phase 1b/2a in SLE With BudoputugWithdrawnNCT06570434Phase 1/2
• A Study of Obexelimab in Patients With Systemic Lupus ErythematosusActive, not recruitingNCT06559163Phase 2
• Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune DiseasesSuspendedNCT06549296Early Phase 1
• A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic DiseaseActive, not recruitingNCT06544330Phase 1
• A Study of GC012F Injection in Subjects With Refractory Systemic Lupus ErythematosusActive, not recruitingNCT06530849Phase 1/2
• REACH (Restore Energy, Activity Can Help) Lupus StudyActive, not recruitingNCT06479213Not applicable
• IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory MyopathyTerminatedNCT06462144Early Phase 1
• A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)WithdrawnNCT06456567Phase 3
• A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus ErythematosusWithdrawnNCT06429800Phase 1
• A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune DiseaseWithdrawnNCT06413511Phase 1
• Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune DiseasesWithdrawnNCT06411639Phase 1
• A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)Active, not recruitingNCT06411249Phase 4
• Myofascial Techniques and Proprioceptive Neuromuscular Facilitation in Patients With Systemic Lupus Erythematosus.CompletedNCT06383104Not applicable
• KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisTerminatedNCT06342960Phase 1/2
• An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).Active, not recruitingNCT06335979Phase 1
• Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus ErythematosusActive, not recruitingNCT06333483Phase 1
• Anti-CD19 CAR-T Cell Therapy in Participants With Moderate to Severe Active Systemic Lupus ErythematosusSuspendedNCT06310811Not applicable
• Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)Active, not recruitingNCT06294236Phase 1
• Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune DiseaseActive, not recruitingNCT06293365Phase 2
• AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus ErythematosusActive, not recruitingNCT06265220Phase 1
• A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune DiseasesActive, not recruitingNCT06255028Phase 1
• A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or LupusWithdrawnNCT06238531Phase 1
• Gradual Withdrawal of Low-dose Glucocorticoid in Clinically Quiescent Systemic Lupus Erythematosus.CompletedNCT06234852Not applicable
• Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus ErythematosusActive, not recruitingNCT06222853Phase 1
• A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy ParticipantsSuspendedNCT06188507Phase 1
• A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)WithdrawnNCT06153095Phase 1/2
• Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.CompletedNCT06150651Phase 1
• SG301-SC Injection Safety Study in Subjects With Systemic Lupus ErythematosusCompletedNCT06144710Phase 1
• Periodontal Status in Patients With Chronic Skin DiseasesCompletedNCT06073613
• A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years OldCompletedNCT06064929Phase 1
• The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)CompletedNCT06056778
• Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs.CompletedNCT06046534
• A Study of Imvotamab in Severe Systemic Lupus ErythematosusTerminatedNCT06041568Phase 1
• Descartes-08 for Patients With Systemic Lupus ErythematosusActive, not recruitingNCT06038474Phase 2
• Clinical Risk Assessment of Cognitive Function in Systemic Autoimmune DiseasesActive, not recruitingNCT06029335
• Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLEActive, not recruitingNCT06015230Phase 1/2
• A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of LupusCompletedNCT06013995Phase 1
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy ParticipantsCompletedNCT05984251Phase 1
• Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusActive, not recruitingNCT05966480Phase 2
• Study of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory RheumatismCompletedNCT05961267
• Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic DiseasesActive, not recruitingNCT05879419Phase 4
• A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)Active, not recruitingNCT05869955Phase 1
• A Study in Participants With Mild-to-moderate Systemic Lupus ErythematosusCompletedNCT05866861Phase 1
• A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus ErythematosusCompletedNCT05856448Phase 2
• Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusActive, not recruitingNCT05843643Phase 3
• A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus ErythematosusActive, not recruitingNCT05835986Phase 1
• The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRBCompletedNCT05818254Not applicable
• An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus ErythematosusCompletedNCT05798117Phase 1/2
• A Phase 2 Clinical Study of MIL62 in Systemic Lupus ErythematosusActive, not recruitingNCT05796206Phase 2
• Validation of Patient E-tool to Measure Systemic Lupus ActivityCompletedNCT05763225
• Effect of Applying Ujjayi Pranayama on Cortisol in Lupus PatientsStatus unknownNCT05748899Not applicable
• 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2CompletedNCT05747651
• Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus ErythematosusStatus unknownNCT05724940
• Engagement in CHildhood-Onset Systemic LupusActive, not recruitingNCT05693571Not applicable
• The Influence of Ketogenic Diet on Lupus Nephritis Patients' ImmunityStatus unknownNCT05689580Not applicable
• A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus ErythematosusCompletedNCT05687526Phase 1
• A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus ErythematosusActive, not recruitingNCT05672576Phase 3
• BAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rheumatoid ArthritisStatus unknownNCT05659407
• A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus ErythematosusActive, not recruitingNCT05648500Phase 3
• Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)Active, not recruitingNCT05639114Phase 3
• A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.Active, not recruitingNCT05637112
• Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular DiseaseStatus unknownNCT05636670
• Laser Acupuncture in Egyptian Systemic Lupus Females With Insulin ResistanceStatus unknownNCT05632029Not applicable
• Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)Active, not recruitingNCT05624749Phase 3
• A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusActive, not recruitingNCT05620407Phase 3
• A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)Active, not recruitingNCT05617677Phase 3
• The Effectiveness of Transcranial Direct Current Stimulation as Adjunctive Treatment for Chronic Daily Headache in Systemic Lupus ErythematosusStatus unknownNCT05613582Not applicable
• Osteoporosis and Fragility Fractures Among SLE Patients. (FRAIL Trial)Active, not recruitingNCT05590390
• In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory DiseasesCompletedNCT05544448Not applicable
• The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)Active, not recruitingNCT05540327Phase 2
• A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusActive, not recruitingNCT05531565Phase 2/3

← Lupus Erythematosus, Systemic overview